|
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
RESEARCH PAPER
1 Department of Medical Oncology, Dana Farber Cancer Institute and Department of Genetics, Harvard Medical School, Boston, Massachusetts 02115, USA , 2 Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA , 3 Abramson Family Cancer Research Institute and Abramson Cancer Center at the University of Pennsylvania and Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19103, USA
Pancreatic ductal adenocarcinoma ranks among the most lethal of human malignancies. Here, we assess the cooperative interactions of two signature mutations in mice engineered to sustain pancreas-specific Cre-mediated activation of a mutant Kras allele (KrasG12D) and deletion of a conditional Ink4a/Arf tumor suppressor allele. The phenotypic impact of KrasG12D alone was limited primarily to the development of focal premalignant ductal lesions, termed pancreatic intraepithelial neoplasias (PanINs), whereas the sole inactivation of Ink4a/Arf failed to produce any neoplastic lesions in the pancreas. In combination, KrasG12D expression and Ink4a/Arf deficiency resulted in an earlier appearance of PanIN lesions and these neoplasms progressed rapidly to highly invasive and metastatic cancers, resulting in death in all cases by 11 weeks. The evolution of these tumors bears striking resemblance to the human disease, possessing a proliferative stromal component and ductal lesions with a propensity to advance to a poorly differentiated state. These findings in the mouse provide experimental support for the widely accepted model of human pancreatic adenocarcinoma in which activated KRAS serves to initiate PanIN lesions, and the INK4A/ARF tumor suppressors function to constrain the malignant conversion of these PanIN lesions into lethal ductal adenocarcinoma. This faithful mouse model may permit the systematic analysis of genetic lesions implicated in the human disease and serve as a platform for the identification of early disease markers and for the efficient testing of novel therapies.
[Keywords: Pancreatic cancer; Ink4a/Arf; PanIN; metastasis; mouse model]
Received October 6, 2003; revised version accepted November 11, 2003.
Article published online ahead of print. Article and publication date are at http://www.genesdev.org/cgi/doi/10.1101/gad.1158703.
4 These authors contributed equally to this work.
5 E-MAIL Ron_Depinho{at}dfci.harvard.edu; FAX (617) 632-6069.
5 E-MAIL Nabeel_el-Bardeesy{at}dfci.harvard.edu; FAX (617) 632-6069.
![]()
CiteULike
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
From the Cover: Nanoparticle-mediated drug delivery to tumor vasculature suppresses metastasis PNAS, July 8, 2008; 105(27): 9343 - 9348. |
||||
![]() |
J. P. Morton, D. S. Klimstra, M. E. Mongeau, and B. C. Lewis Trp53 Deletion Stimulates the Formation of Metastatic Pancreatic Tumors Am. J. Pathol., April 1, 2008; 172(4): 1081 - 1087. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Feldmann and A. Maitra Molecular Genetics of Pancreatic Ductal Adenocarcinomas and Recent Implications for Translational Efforts J. Mol. Diagn., March 1, 2008; 10(2): 111 - 122. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Ding and P. Lengyel p204 Protein Is a Novel Modulator of Ras Activity J. Biol. Chem., February 29, 2008; 283(9): 5831 - 5848. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Konishi, B. Karakas, A. M. Abukhdeir, J. Lauring, J. P. Gustin, J. P. Garay, Y. Konishi, E. Gallmeier, K. E. Bachman, and B. H. Park Knock-in of Mutant K-ras in Nontumorigenic Human Epithelial Cells as a New Model for Studying K-ras Mediated Transformation Cancer Res., September 15, 2007; 67(18): 8460 - 8467. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Kojima, S. M. Vickers, N. V. Adsay, N. C. Jhala, H.-G. Kim, T. R. Schoeb, W. E. Grizzle, and C. A. Klug Inactivation of Smad4 Accelerates KrasG12D-Mediated Pancreatic Neoplasia Cancer Res., September 1, 2007; 67(17): 8121 - 8130. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Jin, S. Park, D. Z. Ewton, and E. Friedman The Survival Kinase Mirk/Dyrk1B Is a Downstream Effector of Oncogenic K-ras in Pancreatic Cancer Cancer Res., August 1, 2007; 67(15): 7247 - 7255. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Funahashi, M. Satake, D. Dawson, N.-A. Huynh, H. A. Reber, O. J. Hines, and G. Eibl Delayed Progression of Pancreatic Intraepithelial Neoplasia in a Conditional KrasG12D Mouse Model by a Selective Cyclooxygenase-2 Inhibitor Cancer Res., August 1, 2007; 67(15): 7068 - 7071. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Zhu, G. Shi, C. Max. Schmidt, R. H. Hruban, and S. F. Konieczny Acinar Cells Contribute to the Molecular Heterogeneity of Pancreatic Intraepithelial Neoplasia Am. J. Pathol., July 1, 2007; 171(1): 263 - 273. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Ji, F. C. Mei, J. Xie, and X. Cheng Oncogenic KRAS Activates Hedgehog Signaling Pathway in Pancreatic Cancer Cells J. Biol. Chem., May 11, 2007; 282(19): 14048 - 14055. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Mahadevan and D. D. Von Hoff Tumor-stroma interactions in pancreatic ductal adenocarcinoma Mol. Cancer Ther., April 1, 2007; 6(4): 1186 - 1197. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. P. Morton, M. E. Mongeau, D. S. Klimstra, J. P. Morris, Y. C. Lee, Y. Kawaguchi, C. V. E. Wright, M. Hebrok, and B. C. Lewis Sonic hedgehog acts at multiple stages during pancreatic tumorigenesis PNAS, March 20, 2007; 104(12): 5103 - 5108. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Carriere, E. S. Seeley, T. Goetze, D. S. Longnecker, and M. Korc The Nestin progenitor lineage is the compartment of origin for pancreatic intraepithelial neoplasia PNAS, March 13, 2007; 104(11): 4437 - 4442. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Ueda, K. Fukamachi, Y. Matsuoka, N. Takasuka, F. Takeshita, A. Naito, M. Iigo, D. B. Alexander, M. A. Moore, I. Saito, et al. Ductal origin of pancreatic adenocarcinomas induced by conditional activation of a human Ha-ras oncogene in rat pancreas Carcinogenesis, December 1, 2006; 27(12): 2497 - 2510. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Tateishi, M. Ohta, F. Kanai, B. Guleng, Y. Tanaka, Y. Asaoka, M. Tada, M. Seto, A. Jazag, L. Lianjie, et al. Dysregulated Expression of Stem Cell Factor Bmi1 in Precancerous Lesions of the Gastrointestinal Tract Clin. Cancer Res., December 1, 2006; 12(23): 6960 - 6966. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. K. Rustgi The molecular pathogenesis of pancreatic cancer: clarifying a complex circuitry. Genes & Dev., November 15, 2006; 20(22): 3049 - 3053. [Full Text] [PDF] |
||||
![]() |
N. Bardeesy, K.-h. Cheng, J. H. Berger, G. C. Chu, J. Pahler, P. Olson, A. F. Hezel, J. Horner, G. Y. Lauwers, D. Hanahan, et al. Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer. Genes & Dev., November 15, 2006; 20(22): 3130 - 3146. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Ijichi, A. Chytil, A. E. Gorska, M. E. Aakre, Y. Fujitani, S. Fujitani, C. V.E. Wright, and H. L. Moses Aggressive pancreatic ductal adenocarcinoma in mice caused by pancreas-specific blockade of transforming growth factor-beta signaling in cooperation with active Kras expression. Genes & Dev., November 15, 2006; 20(22): 3147 - 3160. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Pasca di Magliano, S. Sekine, A. Ermilov, J. Ferris, A. A. Dlugosz, and M. Hebrok Hedgehog/Ras interactions regulate early stages of pancreatic cancer. Genes & Dev., November 15, 2006; 20(22): 3161 - 3173. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. D. Cardiff, M. R. Anver, G. P. Boivin, M. W. Bosenberg, R. R. Maronpot, A. A. Molinolo, A. Y. Nikitin, J. E. Rehg, G. V. Thomas, R. G. Russell, et al. Precancer in Mice: Animal Models Used to Understand, Prevent, and Treat Human Precancers Toxicol Pathol, October 1, 2006; 34(6): 699 - 707. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Abate-Shen A new generation of mouse models of cancer for translational research. Clin. Cancer Res., September 15, 2006; 12(18): 5274 - 5276. [Full Text] [PDF] |
||||
![]() |
M. Singh and L. Johnson Using genetically engineered mouse models of cancer to aid drug development: an industry perspective. Clin. Cancer Res., September 15, 2006; 12(18): 5312 - 5328. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. T. Chan, J. L. Kutok, I. R. Williams, S. Cohen, S. Moore, H. Shigematsu, T. J. Ley, K. Akashi, M. M. Le Beau, and D. G. Gilliland Oncogenic K-ras cooperates with PML-RAR{alpha} to induce an acute promyelocytic leukemia-like disease Blood, September 1, 2006; 108(5): 1708 - 1715. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. B. Deramaudt, M. Takaoka, R. Upadhyay, M. J. Bowser, J. Porter, A. Lee, B. Rhoades, C. N. Johnstone, R. Weissleder, S. R. Hingorani, et al. N-Cadherin and Keratinocyte Growth Factor Receptor Mediate the Functional Interplay between Ki-RASG12V and p53V143A in Promoting Pancreatic Cell Migration, Invasion, and Tissue Architecture Disruption. Mol. Cell. Biol., June 1, 2006; 26(11): 4185 - 4200. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. F. Hezel, A. C. Kimmelman, B. Z. Stanger, N. Bardeesy, and R. A. DePinho Genetics and biology of pancreatic ductal adenocarcinoma. Genes & Dev., May 15, 2006; 20(10): 1218 - 1249. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Bardeesy, A. J. Aguirre, G. C. Chu, K.-h. Cheng, L. V. Lopez, A. F. Hezel, B. Feng, C. Brennan, R. Weissleder, U. Mahmood, et al. From the Cover: Both p16Ink4a and the p19Arf-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse PNAS, April 11, 2006; 103(15): 5947 - 5952. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Kuang, Y. Xiao, X. Liu, T. M. Stringfield, S. Zhang, Z. Wang, and Y. Chen In vivo disruption of TGF-beta signaling by Smad7 leads to premalignant ductal lesions in the pancreas PNAS, February 7, 2006; 103(6): 1858 - 1863. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. H. Hruban, N. V. Adsay, J. Albores-Saavedra, M. R. Anver, A. V. Biankin, G. P. Boivin, E. E. Furth, T. Furukawa, A. Klein, D. S. Klimstra, et al. Pathology of Genetically Engineered Mouse Models of Pancreatic Exocrine Cancer: Consensus Report and Recommendations Cancer Res., January 1, 2006; 66(1): 95 - 106. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. A. Tuveson, L. Zhu, A. Gopinathan, N. A. Willis, L. Kachatrian, R. Grochow, C. L. Pin, N. Y. Mitin, E. J. Taparowsky, P. A. Gimotty, et al. Mist1-KrasG12D Knock-In Mice Develop Mixed Differentiation Metastatic Exocrine Pancreatic Carcinoma and Hepatocellular Carcinoma Cancer Res., January 1, 2006; 66(1): 242 - 247. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Cecena, F. Wen, R. D. Cardiff, and R. G. Oshima Differential Sensitivity of Mouse Epithelial Tissues to the Polyomavirus Middle T Oncogene Am. J. Pathol., January 1, 2006; 168(1): 310 - 320. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-H. Dannenberg, G. David, S. Zhong, J. van der Torre, W. H. Wong, and R. A. DePinho mSin3A corepressor regulates diverse transcriptional networks governing normal and neoplastic growth and survival Genes & Dev., July 1, 2005; 19(13): 1581 - 1595. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Qian, J. Niu, M. Li, P. J. Chiao, and M.-S. Tsao In vitro Modeling of Human Pancreatic Duct Epithelial Cell Transformation Defines Gene Expression Changes Induced by K-ras Oncogenic Activation in Pancreatic Carcinogenesis Cancer Res., June 15, 2005; 65(12): 5045 - 5053. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Khanna and K. Hunter Modeling metastasis in vivo Carcinogenesis, March 1, 2005; 26(3): 513 - 523. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. E. Dowen, T. Crnogorac-Jurcevic, R. Gangeswaran, M. Hansen, J. J. Eloranta, V. Bhakta, T. A. Brentnall, J. Luttges, G. Kloppel, and N. R. Lemoine Expression of S100P and Its Novel Binding Partner S100PBPR in Early Pancreatic Cancer Am. J. Pathol., January 1, 2005; 166(1): 81 - 92. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Keller, B. R. Arenkiel, C. M. Coffin, N. El-Bardeesy, R. A. DePinho, and M. R. Capecchi Alveolar rhabdomyosarcomas in conditional Pax3:Fkhr mice: cooperativity of Ink4a/ARF and Trp53 loss of function Genes & Dev., November 1, 2004; 18(21): 2614 - 2626. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Agbunag and D. Bar-Sagi Oncogenic K-ras Drives Cell Cycle Progression and Phenotypic Conversion of Primary Pancreatic Duct Epithelial Cells Cancer Res., August 15, 2004; 64(16): 5659 - 5663. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. B. Eckert, G. A. Repasky, A. S. Ulku, A. McFall, H. Zhou, C. I. Sartor, and C. J. Der Involvement of Ras Activation in Human Breast Cancer Cell Signaling, Invasion, and Anoikis Cancer Res., July 1, 2004; 64(13): 4585 - 4592. [Abstract] [Full Text] [PDF] |
||||